Skip to content

Viatris VTRS Price / earnings

Price / earnings at other companies

Pfizer logo
PfizerPFE
14.7×
McKesson logo
McKessonMCK
22.3×-3.3×
Cencora logo
CencoraCOR
29.9×+6.0×
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
33.3×-1.4×
Roivant Sciences logo
Roivant SciencesROIV
249.7×+248×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
19.8×-16.3×

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.32B+49.6%
Enterprise value$31.13B+17.7%
P/S1.3×+0.4×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%
Net margin-2%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity+0.1×
Current ratio1.6×-0.1×

Where this comes from

Calculated from Viatris’s reported figures.

Based on the most recent quarter.

The official record: Viatris’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Viatris's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's price / earnings?
Viatris (VTRS) reported price / earnings of 6.5× in Q3 2023.
How has Viatris's price / earnings changed year-over-year?
Viatris's price / earnings decreased by 49.8% year-over-year, from 12.9× to 6.5×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.